Part 2:
The following are additional highlights from the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum, held February 25-27, 2021. Read More
Neurology
ACTRIMS FORUM 2021 – Highlights
March 1, 2021Novel anti-CD20 monoclonal approved in Canada for MS
January 27, 2021Ofatumumab (Kesimpta), a new anti-CD20 monoclonal antibody, has received approval from Health Canada for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with active disease defined by clinical and imaging features. In clinical trials, active disease was defined as at least one relapse or one Gd-enhancing lesion in the previous year.
Multiple sclerosis 2021 – a look ahead
January 13, 2021To start off the new year, NeuroSens asked some MS experts from across Canada what developments in multiple sclerosis research and management we can expect to see. Some issues were necessarily related to COVID-21. But the prognosticators also identified several important questions that may be answered in the months ahead.
This just in – Winners of the 2020 Awards in Multiple Sclerosis
December 16, 2020To close out the pandemic year 2020, we’ve compiled a list of proposed awards for your consideration in the field of multiple sclerosis.